CAS 1100598-32-0

Tepotinib

Description:

Tepotinib is a small molecule inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets the MET receptor tyrosine kinase, which plays a crucial role in cell signaling pathways that regulate cell growth and survival. Tepotinib is particularly effective against tumors that exhibit MET exon 14 skipping mutations, leading to aberrant MET activation. The compound is characterized by its ability to selectively inhibit the MET signaling pathway, thereby reducing tumor proliferation and promoting apoptosis in cancer cells. Tepotinib is administered orally and has been studied for its pharmacokinetics, safety profile, and efficacy in clinical trials. Common side effects may include fatigue, nausea, and liver enzyme elevations. As a targeted therapy, Tepotinib represents a significant advancement in personalized medicine, offering a treatment option for patients with specific molecular profiles in their tumors. Its development underscores the importance of molecular diagnostics in oncology, allowing for more tailored therapeutic approaches.

Formula: C₂₉H₂₈N₆O₂

Synonyms:

• CS-977
• Veledimex
• Tepotinib (EMD 1214063)
• epotinib(EMD 1214063)
• EMD-1214063
• 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile EMD-1214063
• Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl] USP/EP/BP
• EMD1214063,Tepotinib
• 3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-
• EMD 1214063; EMD1214063
• 3-(1-(3-(5-((1-Methylpiperidin-4-yl)Methoxy)pyriMidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile
• MSC2156119
• 3-(1-(3-(5-((1-METHYLPIPERIDIN-4-YL)METHOXY)PYRIMIDIN-2-YL)BENZYL)-1,6-DIHYDRO-6-OXOPYRIDAZIN-3-YL)B
• Tepotinib
• 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile
• 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile

Tepotinib

CAS: 1100598-32-0

Tepotinib (EMD-1214063) is a selective, orally, and ATP-competitive c-MET tyrosine kinase inhibitor. Tepotinib has antitumor effect. Cost-effective and quality-assured.

Formula: C₂₉H₂₈N₆O₂

Purity: 98% - 99.91%

Color and Shape: Solid

Molecular weight: 492.57

Ref: TM-T6121

Tepotinib

CAS: 1100598-32-0

3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile

Formula: C₂₉H₂₈N₆O₂

Purity: 98%

Molecular weight: 492.57

Ref: IN-DG305474

Tepotinib

CAS: 1100598-32-0

Tepotinib

Formula: C₂₉H₂₈N₆O₂

Purity: ≥98%

Molecular weight: 492.57

Ref: 54-BUP04090

Tepotinib

CAS: 1100598-32-0

Formula: C₂₉H₂₈N₆O₂

Molecular weight: 492.58

Ref: 4Z-T-471001

Tepotinib-d5

CAS: 1100598-32-0

Formula: C₂₉H₂₃D₅N₆O₂

Molecular weight: 497.61

Ref: 4Z-T-471002